Page 39 - Read Online
P. 39

Benhammou et al. Hepatoma Res 2020;6:35  I  http://dx.doi.org/10.20517/2394-5079.2020.16                                  Page 11 of 15


               Availability of data and materials
               Not applicable.


               Financial support and sponsorship
               JNB- AASLD and DDRC Pilot and Feasibility  of the National Institutes of Health under award number
               DKP3041301 and the National Center for Advancing Translational Sciences at UCLA, CTSI Grant
               ULTR001881.


               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2020.


               REFERENCES
               1.   Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90.
               2.   Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-9.
               3.   Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic
                   assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
               4.   Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. Design and validation of a histological scoring system for nonalcoholic
                   fatty liver disease. Hepatology 2005;41:1313-21.
               5.   Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009;13:631-47.
               6.   Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology
                   2002;123:1705-25.
               7.   Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an
                   exponential increase in burden of disease. Hepatology 2018;67:123-33.
               8.   Allen AM, Van Houten HK, Sangaralingham LR, Talwalkar JA, McCoy RG. Healthcare cost and utilization in nonalcoholic fatty liver
                   disease: real-world data from a large U.S. claims database. Hepatology 2018;68:2230-8.
               9.   Younossi ZM, Henry L, Bush H, Mishra A. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic
                   steatohepatitis. Clin Liver Dis 2018;22:1-10.
               10.  Younossi ZM, Zheng L, Stepanova M, Henry L, Venkatesan C, et al. Trends in outpatient resource utilizations and outcomes for Medicare
                   beneficiaries with nonalcoholic fatty liver disease. J Clin Gastroenterol 2015;49:222-7.
               11.  Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma
                   in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703.
               12.  Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic
                   fatty liver disease: a multicenter prospective study. Hepatology 2016;63:827-38.
               13.  Lee TY, Wu JC, Yu SH, Lin JT, Wu MS, et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically
                   noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017;141:1307-14.
               14.  Kaplan DE, Serper MA, Mehta R, Fox R, John B, et al. Effects of hypercholesterolemia and statin exposure on survival in a large national
                   cohort of patients with cirrhosis. Gastroenterology 2019;156:1693-706.e12.
               15.  Thrift AP, Natarajan Y, Liu Y, El-Serag HB. Statin use after diagnosis of hepatocellular carcinoma is associated with decreased mortality.
                   Clin Gastroenterol Hepatol 2019;17:2117-25.e3.
               16.  Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, et al. Association between aspirin use and risk of hepatocellular
                   carcinoma. JAMA Oncol 2018;4:1683-90.
               17.  Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, et al. Lipophilic statins and risk for hepatocellular carcinoma and death in
                   patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann Intern Med 2019;171:318-27.
               18.  Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev
                   Gastroenterol Hepatol 2019;16:411-28.
               19.  Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin
                   Gastroenterol Hepatol 2015;13:2140-51.
   34   35   36   37   38   39   40   41   42   43   44